Definition: A growth hormone secretagogue is a compound that makes your pituitary gland release more of its own growth hormone (GH), instead of supplying GH directly. "Secretagogue" just means something that triggers a release. Tesamorelin, CJC-1295 and ipamorelin are examples.
| Type | What it copies | Examples | FDA approved example |
|---|---|---|---|
| GHRH analog | Growth hormone-releasing hormone from the brain | Tesamorelin, CJC-1295 | Tesamorelin (Egrifta), for belly fat in adults with HIV lipodystrophy |
| GHRP (ghrelin-receptor type) | GH-releasing peptides that act on a separate receptor | Ipamorelin, GHRP-6, GHRP-2 | None of the listed examples |
The Egrifta SV label says tesamorelin acts on the pituitary to release GH, which then raises IGF-1 (insulin-like growth factor 1). CJC-1295 is a long-acting GHRH analog; in healthy adults one shot raised GH 2- to 10-fold for 6 days or more (Teichman 2006). Ipamorelin works through the GHRP receptor; in animal tests it released GH without the rise in cortisol seen with GHRP-6 and GHRP-2 (Raun 1998).
Outside tesamorelin, human evidence is thin. Published work on ipamorelin and CJC-1295 is mostly animal studies and small, short studies in healthy volunteers that measured hormone levels, not health outcomes. We found no FDA label for either on DailyMed. They are often sold as "research use only", which means no FDA review of the product in the vial.
These are often stacked (a GHRH analog with a GHRP) or sold as a pre-mixed blend. If one vial holds two peptides, each unit you draw contains some of both, so log the blend as one item with both amounts per vial.
Splitting a blend vial
Read more on Dose Track: Tesamorelin · Ipamorelin · CJC-1295 and ipamorelin blend · Peptide blend calculator